![Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter? | Journal of Nuclear Medicine Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter? | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/63/3/389/F1.large.jpg)
Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter? | Journal of Nuclear Medicine
R/R International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B
![A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images | Scientific Reports A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-023-30533-y/MediaObjects/41598_2023_30533_Fig1_HTML.png)
A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images | Scientific Reports
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma | Haematologica
![Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/55590ce0-5280-4f9f-9092-62815b543c03/ajh26149-fig-0002-m.jpg)
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library
![Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies | Translational Medicine Communications | Full Text Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies | Translational Medicine Communications | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs41231-020-00054-1/MediaObjects/41231_2020_54_Fig1_HTML.png)
Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies | Translational Medicine Communications | Full Text
![Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7784dc0b-c5c2-4480-b6d2-ec9eee64ab62/ajh26149-fig-0001-m.jpg)
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library
![Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials | Semantic Scholar Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/38b30c0b91f9029f8ba2ef978752522888ce3366/3-Table1-1.png)
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials | Semantic Scholar
![Diffuse Large B-Cell Lymphoma Risk Score Calculator: A Tool To Accurat" by Santosh Khanal, Arjun Gampala et al. Diffuse Large B-Cell Lymphoma Risk Score Calculator: A Tool To Accurat" by Santosh Khanal, Arjun Gampala et al.](https://scholarlyexchange.childrensmercy.org/research_month2022/1007/preview.jpg)
Diffuse Large B-Cell Lymphoma Risk Score Calculator: A Tool To Accurat" by Santosh Khanal, Arjun Gampala et al.
![Frontiers | Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma Frontiers | Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma](https://www.frontiersin.org/files/MyHome%20Article%20Library/582567/582567_Thumb_400.jpg)
Frontiers | Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma
![A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era | Scientific Reports A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-61378-4/MediaObjects/41598_2020_61378_Fig1_HTML.png)
A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era | Scientific Reports
![The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society](https://www.astctjournal.org/cms/asset/0d3d7c85-8dc7-4a44-b392-625620393999/gr1.jpg)
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society
![CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2016/jco.2015.64.34.issue-26/jco.2015.65.6520/20161107/images/medium/jco656520t2.gif)